How to adjust the usage and dosage of Brivaracetam/Brivaracetam

Brivaracetam is an anti-epileptic drug widely used to treat focal seizures in epilepsy. It mainly regulates neuronal excitability by selectively binding to neuronal synaptic vesicle protein 2A (SV2A). Compared with traditional antiepileptic drugs, brivaracetam has higher affinity and faster onset of action in terms of pharmacokinetics and pharmacodynamics, so it is often used in clinical practice in patients who need rapid control of epileptic seizures. The adjustment of usage and dosage is individualized based on the patient's age, weight, liver function status and concomitant medication.

For adults and adolescents 16 years of age and older, the usual initial dose is 50 mg to 100 mg per day, taken in two divided doses. Based on the patient's response and tolerance to treatment, the maintenance dose is usually between 50 and 200 mg daily. It is recommended that the interval between each dose adjustment be at least 1 week to allow doctors to observe drug reactions and adverse events. In some cases, where rapid seizure control is required, a higher starting dose, even 100 mg in one dose, may be considered. For patients with impaired hepatic function, especially those with moderate to severe hepatic impairment, it is recommended that the starting dose be reduced to 25 mg to 50 mg daily and the maximum dose be limited to 150 mg daily. Because brivaracetam is metabolized in the liver, its active metabolites are not toxic, but hepatic insufficiency may affect drug clearance.

In addition, brivaracetam can be used in combination with other antiepileptic drugs, especially in patients who do not tolerate levetiracetam, and brivaracetam is often considered an alternative. However, due to possible metabolic interactions with certain drugs (such asCYP enzyme inducers), the drug combination needs to be monitored and the dosage adjusted as appropriate. Special attention should be paid to the risk of additive central depressant effects in patients receiving concomitant sedatives or opioids.

Reference materials:https://www.briviact.com/